You are here

Medicare

JAMA: Leqembi could cost Medicare up to $5B per year

JAMA: Leqembi could cost Medicare up to $5B per year

Medical Marketing and Media

Alzheimer's disease

Flag link:

Eli Lilly damages tripled to $184M in Medicaid rebate fraud case

Eli Lilly damages tripled to $184M in Medicaid rebate fraud case

Fierce Pharma

Flag link:

Lilly expects US Medicare to reverse course, fully cover Alzheimer's drugs

Lilly expects US Medicare to reverse course, fully cover Alzheimer's drugs

Reuters

Alzheimer's disease

Flag link:

Pharma Decries Drug Selection Plans in Medicare Pricing Policy

Pharma Decries Drug Selection Plans in Medicare Pricing Policy

RAPS.org

Inflation Reduction Act

Flag link:

Bill would require Medicare to cover breakthrough devices for four years

Bill would require Medicare to cover breakthrough devices for four years

Medtech Dive

breakthrough devices

Flag link:

CMS lays out plans for negotiating drug prices

CMS lays out plans for negotiating drug prices

BioPharma Dive

Flag link:

Covering new weight loss drugs could strain Medicare, policy experts warn

Covering new weight loss drugs could strain Medicare, policy experts warn

Stat

Flag link:

Will Biden’s ambitious healthcare proposals pass? A look at the 2024 budget

Will Biden’s ambitious healthcare proposals pass? A look at the 2024 budget

Medical Marketing and Media

Flag link:

Biden budget wants to more than double number of negotiated drugs under Medicare, and eliminate hepatitis C

Biden budget wants to more than double number of negotiated drugs under Medicare, and eliminate hepatitis C

Endpoints

Flag link:

Biden proposes expanding Medicare drug negotiation program

Biden proposes expanding Medicare drug negotiation program

Stat

Flag link:

Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report

Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report

Fierce Pharma

Boehringer Ingelheim

Flag link:

Medicare maintains limits on Eisai’s new Alzheimer’s drug

Medicare maintains limits on Eisai’s new Alzheimer’s drug

BioPharma Dive

Alzheimer's disease

Flag link:

CMS Outlines 3 New Drug Pricing Models Targeting Wide Scope of Therapies

CMS Outlines 3 New Drug Pricing Models Targeting Wide Scope of Therapies

American Journal of Managed Care

accelerated approval

Flag link:

Medicare announces plan to recoup billions from drug companies

Medicare announces plan to recoup billions from drug companies

NPR

Inflation Reduction Act

Flag link:

U.S. Supreme Court rebuffs Pfizer plan to help patients pay for heart medication

U.S. Supreme Court rebuffs Pfizer plan to help patients pay for heart medication

Reuters

Flag link:

CMS needs to strengthen its internal controls to ensure Part B drug payment accuracy, OIG finds

CMS needs to strengthen its internal controls to ensure Part B drug payment accuracy, OIG finds

Endpoints

Medicare Part B

Flag link:

Pfizer's Supreme Court challenge of US kickback law is 'far-fetched,' HHS says

Pfizer's Supreme Court challenge of US kickback law is 'far-fetched,' HHS says

Fierce Pharma

Flag link:

A Supreme Court chill across biosimilar 'skinny' labels could halt billions in Medicare savings

A Supreme Court chill across biosimilar 'skinny' labels could halt billions in Medicare savings

Endpoints

Flag link:

President Biden offers another push on drug price savings via executive order

President Biden offers another push on drug price savings via executive order

Endpoints

Flag link:

Decades-old law keeping older adults from trying new weight loss therapies - and companies are paying millions to try to get it changed

Decades-old law keeping older adults from trying new weight loss therapies - and companies are paying millions to try to get it changed

Marketwatch

Flag link:

Pages